× Business
TelecomHealthcareDigital MarketingERPRetailMedia and EntertainmentOil and GasFood and BeveragesMarketing and AdvertisingBanking and InsuranceMetals and MiningLegalComplianceCryptocurrency
Big DataCloudIT ServiceSoftwareMobileSecurityNetworkingStorageCyber SecuritySAPData AnalysisloTBio TechQuality AssuranceEducationE-commerceGaming and VFXArtificial Intelligencescience-and-technology
Cisco DATABASE Google IBM Juniper Microsoft M2M Oracle Red hat Saas SYMANTEC
CEO ReviewCMO ReviewCFO ReviewCompany Review
Startups Opinion Yearbook Readers Speak Contact Us

The Biotech firm Oncolytics enters into an agreement with Adlai Nortye

siliconreview The Biotech firm Oncolytics enters into an agreement with Adlai Nortye

The biotech company Oncolytics which focuses on developing Reolysin enters into an agreement with Adlai Nortye in developing new treatments for cancer and the metabolic diseases. Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs. Together the companies aim at bringing innovative medicines that can eliminate the intensity of diseases as well as methods to eradicate them. Reolysin, the company’s product, is a non-pathogenic, proprietary isolate of the unmodified reo-virus and a first-in-class systemically administered immune-oncology viral agent for the treatment of solid tumors and hematological malignancies.

By entering into an agreement both the companies expect to bring a healthier life and a disease-free environment. Carsten Lu, CEO of Adlai Nortye says "With its impressive clinical data coupled with its unique and novel mechanism, REOLYSIN will be an instrumental component in furthering the development of our oncology pipeline". Adlai Nortye will be responsible for all clinical, regulatory and commercialization activities in its territories. Oncolytics maintains exclusive rights outside of these territories and will be responsible for all development outside of these territories. The agreement will take into consideration the objectives of both the companies in the long term procedure of bringing out new treatments and services. The USD $86.6 Million Regional Licensing Agreement might change the future of both the companies by assisting in developing the medicines and treatments.